AVIR vs. AQST, VTYX, SBTX, XOMA, TERN, ATAI, CRMD, KMDA, NLTX, and ERAS
Should you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Aquestive Therapeutics (AQST), Ventyx Biosciences (VTYX), Silverback Therapeutics (SBTX), XOMA (XOMA), Terns Pharmaceuticals (TERN), Atai Life Sciences (ATAI), CorMedix (CRMD), Kamada (KMDA), Neoleukin Therapeutics (NLTX), and Erasca (ERAS). These companies are all part of the "pharmaceutical preparations" industry.
Aquestive Therapeutics (NASDAQ:AQST) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.
In the previous week, Aquestive Therapeutics had 9 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 11 mentions for Aquestive Therapeutics and 2 mentions for Atea Pharmaceuticals. Aquestive Therapeutics' average media sentiment score of 0.99 beat Atea Pharmaceuticals' score of 0.60 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.
Aquestive Therapeutics has a beta of 2.87, meaning that its stock price is 187% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.
Aquestive Therapeutics currently has a consensus price target of $8.00, suggesting a potential upside of 137.74%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Atea Pharmaceuticals.
Aquestive Therapeutics has higher earnings, but lower revenue than Atea Pharmaceuticals. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Aquestive Therapeutics received 178 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 66.33% of users gave Aquestive Therapeutics an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
Atea Pharmaceuticals has a net margin of 0.00% compared to Atea Pharmaceuticals' net margin of -15.56%. Atea Pharmaceuticals' return on equity of 0.00% beat Aquestive Therapeutics' return on equity.
32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 8.4% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 14.5% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Aquestive Therapeutics beats Atea Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Atea Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atea Pharmaceuticals Competitors List
Related Companies and Tools
